Molecular characterization of gliomas and glioneuronal tumors amid Noonan syndrome: cancer predisposition examined
Margaret Shatara,Kathleen M Schieffer,Marilena Melas,Elizabeth A Varga,Diana Thomas,Brianna A Bucknor,Heather M Costello,Gregory Wheeler,Benjamin J Kelly,Katherine E Miller,Diana P Rodriguez,Mariam T Mathew,Kristy Lee,Erin Crotty,Sarah Leary,Vera A Paulson,Bonnie Cole,Mohamed S Abdelbaki,Jonathan L Finlay,Margot A Lazow,Ralph Salloum,Maryam Fouladi,Daniel R Boué,Elaine R Mardis,Catherine E Cottrell
DOI: https://doi.org/10.3389/fonc.2024.1453309
2024-09-06
Abstract:Introduction: In the setting of pediatric and adolescent young adult cancer, increased access to genomic profiling has enhanced the detection of genetic variation associated with cancer predisposition, including germline syndromic conditions. Noonan syndrome (NS) is associated with the germline RAS pathway activating alterations and increased risk of cancer. Herein, we describe our comprehensive molecular profiling approach, the association of NS with glioma and glioneuronal tumors, and the clinical and histopathologic characteristics associated with the disease. Methods: Within an institutional pediatric cancer cohort (n = 314), molecular profiling comprised of paired somatic disease-germline comparator exome analysis, RNA sequencing, and tumor classification by DNA methylation analysis was performed. Results: Through the implementation of paired analysis, this study identified 4 of 314 (1.3%) individuals who harbored a germline PTPN11 variant associated with NS, of which 3 individuals were diagnosed with a glioma or glioneuronal tumor. Furthermore, we extend this study through collaboration with a peer institution to identify two additional individuals with NS and a glioma or glioneuronal tumor. Notably, in three of five (60%) individuals, paired genomic profiling led to a previously unrecognized diagnosis of Noonan syndrome despite an average age of cancer diagnosis of 16.8 years. The study of the disease-involved tissue identified signaling pathway dysregulation through somatic alteration of genes involved in cellular proliferation, survival, and differentiation. Discussion: Comparative pathologic findings are presented to enable an in-depth examination of disease characteristics. This comprehensive analysis highlights the association of gliomas and glioneuronal tumors with RASopathies and the potential therapeutic challenges and importantly demonstrates the utility of genomic profiling for the identification of germline cancer predisposition.